PerkinElmer Announces Collaboration with Good Start Genetics to Provide Carrier Screening Tests to Broader Women's Health Market
PerkinElmer Inc., a global leader focused on the health and safety of people and the environment, today announced a strategic agreement with Good Start Genetics®, Inc. to expand access to GoodStart Select™ genetic carrier screening tests beyond the in vitro fertilization (IVF) setting the broader women’s health community -- including obstetrics and gynecology (OBGYN) and maternal fetal medicine (MFM) physicians.
“PerkinElmer is committed to offering innovative prenatal screening technology as part of our comprehensive diagnostics portfolio,” said Jim Corbett, president, Human Health, PerkinElmer. “GoodStart Select further expands our maternal fetal health offerings and enables us to provide even more meaningful tools and clinically actionable information and insights to physicians and patients. We look forward to working with Good Start Genetics to extend genetic carrier screening options for those persons planning a pregnancy.”
GoodStart Select is a menu of genetic carrier screening tests that uses sophisticated technologies, including proprietary next-generation DNA sequencing (NGS), to provide highly accurate and clinically actionable genetic information to reproductive partners planning a pregnancy. Test results by GoodStart Select have been shown to provide higher mutation detection rates and fewer missed carriers than traditional screening technologies.
“Our continued success with GoodStart Select in the IVF setting demonstrates the clinical value of our robust menu of tests for guideline-recommended genetic disorders. -- and we are excited that PerkinElmer has chosen GoodStart Select as their genetic carrier screening offering,” said Don Hardison, president and chief executive officer of Good Start Genetics. “Collaborating with PerkinElmer will allow us to reach more of the 60 million reproductive age women who are candidates for genetic carrier screening, and ultimately help more reproductive partners better assess their risks of, and options to avoid, having a baby with a debilitating or fatal inherited genetic disorder.”
|HOW:||Under the terms of the collaboration agreement, PerkinElmer will serve as the exclusive commercial partner of Good Start Genetics in the sales and marketing of GoodStart Select tests to targeted OBGYN and MFM physicians in the United States. The collaboration broadens PerkinElmer’s extensive prenatal screening menu to include highly-validated genetic carrier screening tests included in the GoodStart Select menu.|
|MORE:||Professional societies including the American Congress of Obstetricians & Gynecologists (ACOG), the American College of Medical Genetics and Genomics (ACMG) and national Jewish advocacy societies have published recommendations for carrier screening to detect potential genetic disorders that are relatively common in certain ethnicities. GoodStart Select is designed to identify known, pathogenic mutations for all inherited genetic disorders recommended for testing by the leading reproductive medicine societies and influential advocacy groups, irrespective of a patient’s ethnicity.|
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $2.2 billion in 2013, has about 7,600 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
About Good Start Genetics, Inc.
Good Start Genetics is an innovative molecular genetic information company focused on fundamentally transforming the standard of care in reproductive medicine by providing physicians and their patients with clinically relevant and actionable information concerning inherited genetic disorders. Good Start Genetics' powerful, proprietary next-generation DNA sequencing (NGS) capabilities, supplemented by other proven genetic screening technologies and supported by its commitment to customer care and genetic counseling, enable the company to deliver superior genetic carrier screening test offerings. Through GoodStart Select, the company provides the most comprehensive and clinically actionable menu of genetic carrier screening tests for known and novel mutations that cause inherited genetic disorders. For more information, please visit www.goodstartgenetics.com.
+1 (781) 663-5728
Factors Affecting Future Performance
This announcement contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) the manufacture and sale of products exposing us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with healthcare industry regulations; (15) economic, political and other risks associated with foreign operations; (16) our ability to retain key personnel; (17) significant disruption in our information technology systems; (18) our ability to obtain future financing; (19) restrictions in our credit agreements; (20) our ability to realize the full value of our intangible assets; (21) significant fluctuations in our stock price; (22) reduction or elimination of dividends on our common stock; and (23) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.